Stem Cell-Derived Exosomes

ELEVAI Labs Posts Q3 2023 Earnings, Reports Record Quarterly Revenue

December 11, 2023

ELEVAI Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported its fiscal 2023 Q3 financial results.…

ELEVAI Labs Expands Into European Market With Signing of New Partnership

December 7, 2023

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with…

Biotech

ELEVAI Labs Inks Licensing Deal With Yuva Biosciences to Develop New Topical Skincare Formulations and Aesthetics Products (VIDEO)

November 29, 2023

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announced today the signing of a licensing agreement…

ELEVAI Labs to Accelerate and Expand its Work With Stem Cell-Derived Exosomes After Securing New Research Partnership and Non-Repayable Grant

April 26, 2023

ELEVAI Labs, a medical aesthetic biotechnology company specializing in physician-dispensed skincare, reported today that it secured a stem cell exosome…